Introduction
Matrix metalloproteinases (MMPs) are zinc-dependent endopeptidases that degrade a wide range of basement membrane and extracellular matrix (ECM) components (Massova et al., 1998; Westermarck and Kahari, 1999) . There are currently 23 known MMPs including gelatinases, collagenases, stromelysins, and membranetype MMPs (Massova et al., 1998) . All MMPs are secreted in latent forms and require removal of the PRCGVPD sequence-containing prodomain for activity (Massova et al., 1998; Ellerbroek and Stack, 1999) . Other MMP regulatory domains include the zincdependent catalytic domain and the hemopexin-like domain, which plays a functional role in substrate binding and interaction with the tissue inhibitors of metalloproteinases (TIMPs), a family of endogenous speci®c MMP protein inhibitors (Kahari and Saarialho-Kere, 1999) . MMP transcription is also regulated through sites in the promoter speci®c for AP-1, AP-2, and NF-kB transcription factors ( Curran and Murray, 2000; Westermarck and Kahari, 1999; Ricca et al., 2000) . Therefore, MMP activity may be regulated at the level of transcription, secretion, activation, and inhibition.
MMPs are important for normal structural remodeling during development and are expressed in many normal tissues (Khasigov et al., 2001) . MMPs also play a crucial role in the wound healing process ( Ravanti and Kahari, 2000) . However, abnormal expression and/or activation of MMPs promotes pathogenesis in a wide variety of diseases, including atherosclerosis (George, 2000) , neurodegenerative disease (Beuche et al., 2000; Lim et al., 1996) , diabetic nephropathy (McLennan et al., 2000) , osteoarthritis (Elliott and Cawston, 2001) , rheumatoid arthritis ( Elliott and Cawston, 2001) , and cancer ( Curran and Murray, 2000; Stamenkovic, 2000) . During tumor development, MMP activation promotes tumor invasion and metastasis through degradation of basement membrane and either invasion into surrounding tissue or intravasation through endothelial cells into the blood stream (Stamenkovic, 2000) . Several cancers show increased MMP activation, including breast carcinoma (Duy et al., 2000) , bladder carcinoma (Kanayama, 2001) , multiple myeloma (Kelly et al., 2000) , and neuroblastoma (Ara et al., 1998 (Ara et al., , 2000 Ribatti et al., 1998; Sugiura et al., 1998) .
We are interested in neuroblastoma tumor development and progression. Neuroblastoma is a peripheral nervous system tumor arising through improper dierentiation of neural crest-derived tissues during development (Castleberry, 1997; Cianfarani and Rossi, 1997) . Although low-grade neuroblastoma is treatable, highly metastatic tumors remain incurable and refractory to current conventional treatment modalities (Philip, 1992) . The best prognostic indicator for neuroblastoma is N-Myc (Corvi et al., 1997) with NMyc overexpression leading to poor prognosis (Brodeur et al., 1984; Schwab et al., 1984; Corvi et al., 1997) . We have previously shown that N-Myc increases cell growth, neovascularization, Type I insulin-like growth factor receptor (IGF-IR) expression, and tumorigenecity of SHEP cells when coexpressed with the anti-apoptotic protein Bcl-2. These results suggest a role for cooperativity of these two proteins in neuroblastoma tumor growth and metastasis, which may be mediated through the eect on IGF-IR expression and signaling (Jasty et al., 2001) .
The current study investigates the eect of N-Myc and Bcl-2 on SHEP neuroblastoma MMP expression and invasion. N-Myc and Bcl-2 when coexpressed increase MMP-2 protein expression and secretion, ultimately leading to increased activation. SHEP/Bcl-2 and SHEP/ N-Myc/Bcl-2 cells also have increased MMP-2 mRNA expression. MMP-7 is converted from the proform to the active form in both Bcl-2 overexpressing cells and cells coexpressing N-Myc and Bcl-2. However, other MMPs, including MMP-9, MMP-13, and MTI-MMP, are unaected by N-Myc or Bcl-2 expression. Bcl-2 expression alone slightly increases MMP-2 secretion; however, an endogenous MMP-2 inhibitor, TIMP-2, is upregulated in these cells, preventing increased MMP-2 activity. Invasion through an arti®cial basement membrane is increased in N-Myc/Bcl-2 overexpressing cells, preventable through the use of an MMP-2 speci®c inhibitor. The IGF-IR regulates MMP-2 in other systems, and in the current study overexpression of IGF-IR also increases MMP-2 mediated invasion. Together, these results suggest that the reported increased tumorigenic potential of SHEP neuroblastoma cells expressing both N- Myc and Bcl-2 (Jasty et al., 2001 ) is in part due to the upregulation of MMP-2 expression, secretion, and activation, resulting in increased invasive capabilities.
Results

MMP-2 is regulated by N-Myc and Bcl-2
The gelatinases, MMP-2 and MMP-9, are widely implicated in the invasion of tumor types (Curran and Murray, 2000; Westermarck and Kahari, 1999) , including neuroblastoma (Taguchi et al., 1997; Sugiura et al., 1998; de Veas et al., 1995) . The current study investigates the expression and secretion of MMP-2, the gelatinase most correlated with advanced stage neuroblastoma tumors (Ribatti et al., 1998; de Veas et al., 1995; Ara et al., 2000) . SHEP/Vector, SHEP/N-Myc, SHEP/Bcl-2, and SHEP/N-Myc/Bcl-2 cells were plated on either plastic tissue culture dishes or Matrigel arti®cial basement membrane-coated dishes to stimulate MMP activation. Since MMPs are secreted into the extracellular space upon activation, whole cell lysates and conditioned media were collected. Upon exposure to bare plastic, SHEP/N-myc and SHEP/Bcl-2 cells show slightly enhanced MMP-2 protein expression, while SHEP/N-Myc/Bcl-2 cells dramatically increase the expression of MMP-2 (Figure 1a ). To determine if this increase in expression also increases secretion of MMP-2 into the media, which is necessary for MMP-2 activation, conditioned media were analysed for MMP-2 expression. SHEP/Bcl-2 cells show a slight increase in expression of MMP-2 in the media, while SHEP/N-Myc/ Bcl-2 cells show a large increase in secreted MMP-2 (Figure 1b) . MMP-2 expression may be transcriptionally controlled through the AP-1 and AP-2 response elements in the MMP-2 promoter (Stamenkovic, 2000; Kahari and Saarialho-Kere, 1999) . To investigate the eect of N-Myc and Bcl-2 on MMP-2 transcription, RNA samples from each cell line were collected and analysed using the XpressPack MMP-2 mRNA Expression Analysis kit (Chemicon) as described. All four cell lines display MMP-2 RNA levels at or above the level of the PCR positive control (Figure 1c ). N-Myc alone slightly decreases MMP-2 RNA expression when compared to SHEP/Vector cells; however, this decrease does not reach statistical signi®cance (P=0.1270). In contrast, SHEP/Bcl-2 and SHEP/N-Myc/Bcl-2 cells show a signi®cant increase in MMP-2 RNA (SHEP/Bcl-2, P=0.0045; SHEP/N-Myc/Bcl-2, P=0.0080) compared to vector transfected controls. Together, these data imply that N-Myc and Bcl-2 cooperate to increase both MMP-2 expression and secretion.
Given the wide variety of MMPs, the eect of NMyc and Bcl-2 overexpression on a select group of MMPs known to play a role in tumorigenesis, including MMP-9, MMP-7, MMP-13, and MT1-MMP, was investigated. MMP-7, a stromelysin known to activate other MMPs (Hidalgo and Eckhardt, 2001) , is processed from the proform to the active form in both SHEP-Bcl-2 and SHEP/N-Myc/Bcl-2 cells ( Figure  2a ). MMP-9, a gelatinase with similar speci®city for substrate as MMP-2, shows slightly increased secretion in the SHEP/vector cells and the SHEP/Bcl-2 cells (Figure 2a ). MMP-13 activates MMP-2 in some cell types (Stamenkovic, 2000) . However, there is no MMP-13 regulation in the cell lines utilized in this study (Figure 2a) . Finally, expression of MTI-MMP, a membrane bound MMP capable of activating MMP-2 at the cell membrane ( Ellerbroek and Stack, 1999) , was investigated. MT1-MMP expression remained relatively constant in all cell types on both plastic and Matrigel, indicating no regulation by N-Myc, Bcl-2, or both ( Figure 2b ).
MMP-2 activity increases in SHEP/N-Myc/Bcl-2 cells
Several factors regulate MMP activity, including activation through the membrane-type MMPs and inhibition through the TIMPs. In the current study, MMP-2 activity was measured using gelatin zymogra-phy. Zymography indicated an approximately twofold increase in MMP-2 gelatinase activity in the SHEP/NMyc/Bcl-2 cells (Figure 3 ). MMP-9 activity levels remained constant, however, despite the varying levels of MMP-9 secretion detected using Western blot analysis (data not shown). Therefore, increases in MMP expression and secretion do not always increase MMP activity. Endogenous inhibitors of the MMPs, named TIMPs, inhibit the activation of secreted MMPs. TIMP-1 and TIMP-2 levels were measured in all four cell lines. TIMP-1 levels in the SHEP/Bcl-2 (Figure 5b ). Although these cells invade, they are not capable of proliferating under serum-free conditions, indicating that the changes in cellular invasion detected are due to an increase in invasive potential, not an increase in the number of cells due to proliferation (data not shown). In summary, SHEP/N-Myc/Bcl-2 cells show the highest degree of invasion, which correlates with the levels of MMP-2 secretion and activation.
To examine the role of MMP-2 on the invasive phenotype, MMP-2 activity was blocked using a pharmacologic inhibitor of MMP-2 (MMP-2 Inhibitor I, Calbiochem). SHEP/Vector, SHEP/N-Myc, SHEP/ Bcl-2, and SHEP/N-Myc/Bcl-2 cells were incubated with 20 mM MMP-2 inhibitor and plated in the invasion assay described above. The inhibitor prevents cell invasion, with all invasion assay membranes resembling that of the SHEP/vector control cells (Figure 5a ). Quantitatively, all of the cell lines show similar invasion when incubated with the inhibitor (Figure 5b) . Therefore, inhibiting MMP-2 activation using a pharmacologic inhibitor reduces all levels of invasion to near control levels. This experiment suggests that the increases in invasion seen are MMP-2 mediated.
We have previously shown an increase in IGF-IR expression in SHEP/N-Myc/Bcl-2 (Jasty et al., 2001) . Increased IGF-IR levels in tumor cells can cause increased proliferation (Singleton et al., 1996; Surmacz et al., 1998) and increased tumor growth , implicating IGF-IR signaling in tumor progression. To support a role for the IGF-IR in neuroblastoma invasion, IGF-IR overexpressing SHEP cells were used in the invasion assay described above with or without MMP-2 inhibitor present. SHEP/IGF-IR cells have increased cellular invasion, although not as large an increase as the SHEP/N-Myc/Bcl-2 cells Furthermore, IGF-IR overexpression increases MMP-2 RNA levels detected in the assay described above (data not shown), implicating the IGF-IR in the transcriptional regulation of MMP-2. The pharmacological MMP-2 inhibitor prevents cell invasion in SHEP/IGF-IR cells as well, bringing the level of cell invasion to control levels. Therefore, the IGF-IR increases MMP-2 mediated cell invasion on its own, demonstrating a potential role for this protein in neuroblastoma cell invasion.
Discussion
The matrix metalloproteinases are widely expressed in human tissues and play an integral role in tumor cell invasion and metastasis (Westermarck and Stamenkovic, 2000) . Current hypotheses suggest that MMP activation promotes tumor invasion through degradation of basement membrane components and metastases through increased cellular intravasation through endothelial cells into the blood stream (Stamenkovic, 2000) . Many tumor types have increased MMP activation corresponding to an increased malignant phenotype, including neuroblastoma (Ara et al., 1998 (Ara et al., , 2000 Ribatti et al., 1998; Sugiura et al., 1998) . Neuroblastoma is a pediatric tumor composed of several cell types, including neuroblasts, chrondrocytes, glial cells, and melanocytes, which have varying degrees of tumorigenic potential (Shimada et al., 1999) . Established cell lines representing either neuroblasts or glial/stromal cells are used to investigate molecular changes which result in a tumorigenic phenotype, such as the SHEP and SH-SY5Y cell lines derived from the heterogeneous SK-N-SH cell line (Biedler et al., 1988) . SHEP cells are nontumorigenic and usually express undetectable levels of N-Myc or Bcl-2 protein (Jasty et al., 2001) . Therefore, this cell line is a useful model for studying the role of N-Myc and Bcl-2 expression on speci®c tumorigenic properties, including invasion. NMyc and Bcl-2 overexpression in SHEP cells leads to increased cell growth, angiogenesis, and tumor formation in nude mice (Jasty et al., 2001) . The current study seeks to establish a role for N-Myc and Bcl-2 cooperativity in invasion through the regulation of the MMPs.
The gelatinases, MMP-2 and MMP-9, are implicated in the invasion of neuroblastoma cells. MMP-2 and -9 are both detected in primary tumors, with MMP-2 localized to both neuroblasts and stromal cells, while MMP-9 is localized primarily to stromal, vascular, and to Vector-Inhibitor and a double asterisk (**) indicates statistical signi®cance (P50.005) in the inhibitor-treated cell line compared to the corresponding cell line without inhibitor present using the Alternate Welch t-test. ANOVA analysis was also performed to con®rm statistical signi®cance Oncogene N-Myc and Bcl-2 mediate MMP-2 in neuroblastoma D Noujaim et al perivascular cells (Sugiura et al., 1998) . MMP-2 is associated with high-grade tumors with poor clinical outcome, whereas MMP-9 expression has no correlation with tumor grade (Ara et al., 1998 (Ara et al., , 2000 . We therefore began our studies with MMP-2.
MMP-2 is regulated by several dierent mechanisms. First, MMP-2 expression levels may be altered through transcriptional regulation, primarily by AP-1 and AP-2 response elements in the MMP-2 promoter (Stamenkovic, 2000; Kahari and Saarialho-Kere, 1999) . Secondly, MMPs are activated through proteolytic cleavage of the latent proform into the active form (Stamenkovic, 2000) . Latent MMP-2 is activated at the cell membrane by MT1-MMP, then secreted into the extracellular space (Itoh et al., 2001; Nagase, 1998; Murphy et al., 1999) . Finally, upon secretion, MMP proteolytic activity is regulated by the TIMPs, which bind to the zinc-binding site of active MMPs (Westermarck and . Complex formation has been most widely studied between TIMP-2 and MMP-2 (Stamenkovic, 2000; Kahari and SaarialhoKere, 1999) . TIMP-2 initially forms a ternary complex with latent MMP-2 and MT1-MMP, which serves to localize MMP-2 to the cell membrane (Nagase, 1998). However, upon secretion and subsequent activation of MMP-2, TIMP-2 binding inhibits further MMP-2 activity (Nagase, 1998).
In the current study, we examine MMP-2 expression, secretion, activation, and inhibition in four neuroblastoma cell lines. In SHEP/vector and SHEP/N-Myc cells, which do not display characteristics of tumorigenic cells (Jasty et al., 2001) , MMP-2 is expressed, but is only secreted in low levels. SHEP/Bcl-2 cells, which are also nontumorigenic, do display increased MMP-2 expression and secretion; however, MMP-2 activity is low. SHEP/N-Myc/Bcl-2 cells, which are tumorigenic in both in vitro and in vivo assays (Jasty et al., 2001) , show a large increase in MMP-2 expression, secretion, and activation. Our data agree with MMP-2 pro®les in other neuroblastoma cell lines (Taguchi et al., 1997; Ribatti et al., 1998; Bjornland et al., 2001) . Previous works show that there is no increase in MMP-2 activity in cell lines displaying only ampli®ed N-Myc (Taguchi et al., 1997) . In our study, expression of both N-Myc and Bcl-2 substantially increases MMP-2 secretion and activity, suggesting that cooperation between N-Myc and Bcl-2 is necessary for an increase in MMP-2 activity in human neuroblastoma.
MMP-2 activation is altered by both expression of MT1-MMP, an activator of MMP-2 (Murphy et al., 1999; Nagase, 1998) , and TIMP-2, an inhibitor of MMP-2 (Yu et al., 1996) . MT1-MMP levels remained unchanged in all of the transfected cell lines examined in this study. Therefore, although MT1-MMP is expressed, which is required for MMP-2 activation, the dierences in activation detected are not due to alterations in MT1-MMP. This is in contrast to cell lines naturally expressing increased levels of N-Myc, in which MMP-2 levels remain unaltered, but MT1-MMP levels are increased (Taguchi et al., 1997) . However, alteration in either of these proteins results in the same eect: an increase in MMP-2 activation. Therefore, it is conceivable that dierent neuroblastoma tumors and cell lines would activate MMP-2 through dierent means.
TIMPs are endogenous inhibitors of MMP activation (Easton et al., 1998) . TIMP-1 levels are not aected by N-Myc or Bcl-2 overexpression in this study. TIMP-2, which is speci®c for MMP-2, is highly expressed in the SHEP/Bcl-2 cells, which likely explains the low level of MMP-2 activity in these cells. The SHEP/N-Myc/Bcl-2 cells have no detectable TIMP-2 expression. Therefore, the MMP-2/TIMP-2 ratio is shifted in favor of MMP-2 activation. The importance of this ratio in determining both MMP-2 activity and cellular invasion is described in numerous tumor types (Kahari and Saarialho-Kere, 1999) . Decreased TIMP-2 expression shows a positive correlation with poor clinical outcome in human neuroblastoma (Ara et al., 1998) .
Although MMP-2 levels, secretion, and activation are increased in the more tumorigenic SHEP/N-Myc/ Bcl-2 cells, we tested other MMPs for regulation by NMyc and Bcl-2 in this system. MMP-9 has also been widely studied in both primary neuroblastoma tumors and in neuroblastoma cell lines (Ara et al., 1998; Ribatti et al., 1998 Ribatti et al., , 2001 Bjornland et al., 2001 ). In the current study, MMP-9 expression is increased in SHEP/Bcl-2 cells, but decreased in SHEP/N-Myc and SHEP/N-Myc/Bcl-2 cells, with no corresponding change in activity. In MCF-7 breast cancer cells, Bcl-2 overexpression leads to increased NF-kB dependent transcription of MMP-9 (Ricca et al., 2000) . NF-kB regulation of MMP-9 is also detected in neuroblastoma cells during spontaneous conversion from epithelial to neuroblast phenotype (Farina et al., 1999) . However, the mechanism underlying N-Myc repression of MMP-9 is unclear. In neuroblastoma, the induction of dierentiation leads to MMP-9 upregulation (Chambaut-Guerin et al., 2000) . Our hypothesis is that NMyc expression leads to a less dierentiated phenotype, which allows the cells to increase growth and motility. Therefore, this study would support our current hypothesis.
MMP-13 and MMP-7 levels were also examined in this study. MMP-13, which is activated by MT1-MMP and subsequently activates MMP-2 (Stamenkovic, 2000) , is not regulated by N-Myc or Bcl-2 in SHEP neuroblastoma cells. This is not surprising considering the unaltered expression of MT1-MMP. Therefore, once again MMP-2 activation is likely regulated independently of MT1-MMP and MMP-13 in these cells. MMP-7 is the smallest of the MMPs and is implicated in MMP-2 processing (Barille et al., 1999) . MMP-7 shows increased proteolytic processing in both the SHEP/Bcl-2 and SHEP/N-Myc/Bcl-2 cells. However, given the increase in both of these cell types, MMP-7 is likely not involved in MMP-2 activation and cellular invasion in SHEP cells. MMP-7 cleaves Fas ligand, a mediator of cellular apoptosis, resulting in tumor resistance to chemotherapeutic drug treatment (Mitsiades et al., 2001 ). Since Bcl-2 is a known anti-N-Myc and Bcl-2 mediate MMP-2 in neuroblastoma D Noujaim et al apoptotic agent, the eect on MMP-7 in both of these cell lines may be due to the expression of Bcl-2 irrespective of N-Myc. MMPs' ultimate function in tumors is to increase cellular invasion and metastasis (Ribatti et al., 1998) . We examined cellular invasion using a modi®ed Boyden chamber assay with or without the chemical MMP-2 speci®c inhibitor. Invasion is signi®cantly increased in the SHEP/N-Myc/Bcl-2 cells, which corresponds to the increased level of MMP-2 activation detected in these cells. When MMP-2 Inhibitor I is added, invasion is brought to control levels in all cell lines. Given all of the combined evidence, we believe that the increased invasive phenotype seen in the SHEP/N-Myc/Bcl-2 cells is due to increased MMP-2 secretion and activation. MMP-2 is localized to invadopodia and lamellipodia in invasive cells (Chen and Wang, 1999) , indicating a speci®c role for MMP-2 in invasion of cells through the basement membrane. Several pharmacologic inhibitors have been designed to prevent MMP activity in tumor treatment protocols (Hidalgo and Eckhardt, 2001) . Several classes of inhibitors exist, and many, including the MMP-2 inhibitor Marimastat, are in Phase III clinical trials (Hidalgo and Eckhardt, 2001) . Therefore, an understanding of MMP regulation in neuroblastoma may be critical for the development of new, more ecacious, treatment protocols.
MMP-2 expression levels may be altered through the regulation of transcription, primarily through the AP-2 response element ( Westermarck and Kahari, 1999) . Therefore, signal transduction pathways downstream from receptor tyrosine kinases which result in AP-2 promoter activity may lead to increased MMP-2 expression. We recently reported an increase in IGF-IR levels in SHEP/N-Myc/Bcl-2 cells (Jasty et al., 2001) . IGF-I also induces early changes associated with migration in neuroblastoma cells, such as process formation and random motility (Leventhal et al., 1999; Leventhal and Feldman, 1997) , which may precede cellular invasion (Leventhal et al., 1999) . Our hypothesis is that the overexpression of IGF-IR induced by N-Myc and Bcl-2 coexpression may result in increased IGF signaling leading to MMP-2 mediated invasion. We therefore investigated the eect of IGF-IR expression alone on MMP-2 mediated invasion in this study. IGF-IR overexpression increased the level of invasion, although not to the level shown by the SHEP/N-Myc/Bcl-2 cells. This suggests that a portion of the increased MMP-2 mediated invasion detected may be a result of activity of the IGF system.
The IGF system is closely associated with MMP-2 regulation in several tumor types. Overexpression of IGF-IR in a poorly invasive lung carcinoma cell line increases MMP-2 mRNA and protein expression (Long et al., 1998) . In contrast, when expression of IGF-IR is prevented through antisense oligonucleotides, MMP-2 transcription, expression, activation, and subsequent invasion are reduced in a highly invasive cell line (Long et al., 1998) . Several signaling pathways activated downstream from the IGF-IR are also implicated in MMP upregulation. MMP-9 is upregulated by the mitogen-activated protein kinases (MAPKs) and the jun amino-terminal kinases (JNKs) in vascular smooth muscle cells (Cho et al., 2000) , human epidermal keratinocytes (Zeigler et al., 1999; McCawley et al., 1999) , and in numerous tumor types (Lakka et al., 2000; Gum et al., 1997; Crowe et al., 2001) . In v-src transformed cells, which are invasive, MMP-2 is upregulated through constitutive, sustained activation of the MAPK kinase MEK1 (Kurata et al., 2000) . The phosphatidylinositol-3,4,5-kinase (PI-3K) pathway, also initiated by IGF-IR activation, increases MMP-9 secretion in ovarian cancer cells and MMP-2 production in MDA-MB-231 highly invasive mammary epithelial cells (Sugiura and Berditchevski, 1999) . We have previously shown that increased IGF-IR expression in SHEP neuroblastoma cells leads to MAPK activation in the absence of IGF ligand (van Golen et al., 2000) . Therefore the increase in IGF-IR expression in SHEP/N-Myc/Bcl-2 cells may lead to sustained MAPK activation, resulting in continued activation of the AP-2 promoter and increased MMP-2 expression. These ®ndings suggest that N-Myc and Bcl-2 cooperation may lead to MMP-2 upregulation through their eect on IGF-IR expression. Currently, studies are underway to elucidate the role of the IGF-IR and downstream signaling pathways in the regulation of MMP-2 transcription, secretion, activation, and cellular invasion. (Jasty et al., 2001; Singleton et al., 1996) are maintained in DMEM+10% CS+250 mg/ml G418 Oncogene N-Myc and Bcl-2 mediate MMP-2 in neuroblastoma D Noujaim et al (Gibco ± BRL). These constructs and transfection into SHEP cells are as previously described (Jasty et al., 2001; Singleton et al., 1996) . Cells are routinely subcultured through removal of the cells from the plates with trypsin-EDTA.
Materials and methods
Materials
Western immunoblotting
Western blot analyses are performed as previously described (Leventhal et al., 1995) . Brie¯y, cell lysates are collected using RIPA buer (20 mM Tris (pH 7.4), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 0.1% SDS, 1% sodium deoxycholate, 1% Triton X-100, 1 mM sodium orthovanadate, 0.1 trypsin inhibitor units/ml, 10 mg/ml leupeptin, and 100 mg/ml PMSF). For experiments using conditioned media, serumfree media is added to the plates for 24 h. The media is then collected and concentrated using Centriprep 30 centrifugal concentrator tubes (Amicon, Inc., Beverly, MA, USA). Protein concentrations are determined in both whole cell lysates and concentrated media using the Bio-Rad DC protein assay kit. Seventy mg of protein are loaded and run on an SDS ± PAGE gel prepared with Bio-Rad gel reagents. After transfer to nitrocellulose membranes, the membranes are incubated with the indicated primary antibody overnight at 48C. All membranes are further incubated with horseradish peroxidase conjugated anti-rabbit secondary antibody (Santa Cruz Biotechnology, 1 : 2000 dilution) for 1 h, developed with Lumiglo Chemiluminescent Detection Reagents (Cell Signaling), and exposed to ®lm (Hyper®lm-ECL, Amersham). Blots shown are 1 or 3 independent experiments performed.
Zymography
Cells are plated on matrigel-coated tissue culture plates (BD Biosciences) and grown for 24 h. Conditioned media is then prepared and collected as described above. Seventy mg of protein are loaded onto a 10% gelatin zymography gel (BioRad Laboratories) and electrophoretically separated. Gels are rinsed in 2.5% Triton X-100, incubated in incubation buer (0.05 Tris-HCl (pH 7.5), 0.15 M NaCl, 0.01 M CaCl 2 , and 1 mM ZnCl 2 ) overnight, and stained for 15 min with Coomassie Blue R250. Blots are destained in acetic acid overnight, then visualized and photographed. MMP-2 and MMP-9 zymography standards are used as positive controls for each experiment.
MMP-2 mRNA detection assay
Cells are plated on plastic tissue culture dishes and grown to 70% con¯uence. RNA is harvested using Trizol reagent per the manufacturer's protocol. MMP-2 mRNA levels are quanti®ed using the XpressPack MMP-2 mRNA Expression Analysis Kit (Chemicon, Temecula, CA, USA) followed by bioluminescent detection using the ChemFLASH AquaLite Streptavidin Kit (Chemicon) according to kit instructions. Brie¯y, cDNA is synthesized from the harvested RNA using Olig d(T) primers. Next, PCR is performed using the included biotinylated MMP-2-speci®c primers, which amplify only spliced RNA. The resultant PCR product is hybridized to a 96-well plate coated with an oligonucleotide capture probe. The complex is reacted with streptavidin conjugated to the photoprotein aequorin. After washing, wells are injected with a calcium-containing trigger buer and the intensity of emitted light is read for 2 s on a microplate luminometer. The hybridization positive and negative controls are those provided by Chemicon. Data are presented as mean relative light units (7 no trigger blank reading)+s.e.m. Data are represented as the mean optical density+s.e.m. Statistical analyses are performed using analysis of variance (ANOVA) and a Student's t-test.
Cell invasion assay
Cell invasion assays are performed using the Chemicon International Invasion Assay Kit (ECM550) based upon a modi®ed Boyden chamber assay. This assay is performed according to the manufacturer's recommended protocol. Brie¯y, cells are counted and plated at a density of 1.0610 6 cells/ml serum-free DMEM in one chamber per well in a 24-well tissue culture plate. Complete medium is placed in the bottom chamber of the plate. Cells are allowed to invade for 72 h. Cells remaining on the top surface of the ®lter are removed using sterile cotton swabs. The ®lters are then stained with the provided staining solution for 20 min, rinsed in water, and allowed to dry. Filters are visualized and photographed using a Nikon Diaphot microscope. For quanti®cation, ®lters are immersed in acetic acid to dissolve the stained cells. Stained cells are placed in a 96-well tissue culture plate, and optical density is measured at a wavelength of 560 nm using a LabSystems Fluoroskan Ascent FL uorimeter (LabSystems, Franklin, MA, USA). For those conditions requiring inhibitor, the MMP-2 speci®c inhibitor (MMP-2 Inhibitor I, Cat. #444244, Calbiochem, La Jolla, CA, USA) is added at a concentration of 10 M for the duration of the experiment. Data are presented as the mean optical density+s.e.m. Statistical analyses are performed using analyses of variance (ANOVA) and a Student's t-test.
